MedTrace Logo

Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients

NCT00116584 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-oxygen driven nebulization.

Conditions

  • Bronchiolitis

Interventions

DRUG

heliox

continuous heliox therapy

DRUG

oxygen

continuous oxygen therapy

Sponsors & Collaborators

  • University of Louisville

    lead OTHER

Principal Investigators

  • In K Kim, MD · University of Louisville, Dept. of Pediatrics, Div. of Pediatric Emergency Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-03-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116584 on ClinicalTrials.gov